According to the latest report by IMARC Group, titled “Hydroxychloroquine Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026″,Offers a comprehensive analysis of the industry, which comprises insights on hydroxychloroquine market share. The global hydroxychloroquine market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to exhibit robust growth during 2021-2026.
Industry Definition and Application:
Hydroxychloroquine (HCQ) is a derivative of chloroquine with the molecular formula (C18H26ClN3O). It is a chemotherapeutic drug deployed to prevent and treat malaria by targeting erythrocytic forms of malarial parasites. It is widely prescribed to treat rheumatoid arthritis, Q fever, systemic lupus erythematosus, and Porphyria Cutanea Tarda (PCT). It possesses anti-autophagy, antimalarial, and immunosuppressive properties as it hinders the immune system and presents cytokines and antigens in the body. As a result, hydroxychloroquine is widely available in the form of tablets across hospitals and retail pharmacies.
Request Free Sample Report: https://www.imarcgroup.com/hydroxychloroquine-market/requestsample
Market Trends
The market is primarily driven by the growing prevalence of malaria and pesticide resistance among vectors. In addition, HCQ is widely used as a disease-modifying anti-rheumatic drug (DMARD), which is contributing to market growth. Moreover, the recent onset of the coronavirus disease (COVID-19) pandemic and the increasing clinical trials and experiments underway to determine the efficacy of the drug against the virus represents another major growth-inducing factor. Besides this, the increasing population, rising health awareness, and the growing incidences of autoimmune diseases, including lupus erythematosus and rheumatoid arthritis among individuals, are accelerating the product adoption rate. Along with this, the implementation of favorable government policies to encourage global health is accelerating the product adoption rate. Furthermore, the extensive research and development (RD) activities conducted by key market players in the field of medical sciences, easy access to quality healthcare, and approval of novel drugs are propelling the market growth.
Report Segmentation:
The report has segmented the market into the following categories:
Breakup by Dosage Type:
- 200 Mg
- 300 Mg
- 400 Mg
- Others
Breakup by Distribution:
- Hospital Pharmacies
- Retail Pharmacies
- Others
Breakup by Application:
- Rheumatoid Arthritis
- Lupus Erythematosus
- Malaria
- Coronavirus (COVID-19)
- Others
Breakup by Grade:
- USP Standards Grade
- EP Standards Grade
- Pharmaceutical Standards Grade
- Others
Breakup by Route of Administration:
- Oral
- Intravenous
Breakup by Region:
- North America: (United States, Canada)
- Asia Pacific: (China, Japan,India, South Korea, Australia, Indonesia, Others)
- Europe: (Germany, France,United Kingdom, Italy, Spain, Russia, Others)
- Latin America: (Brazil, Mexico, Others)
- Middle East and Africa
Ask Analyst for Customization and Explore Full Report with TOC List of Figure: https://www.imarcgroup.com/request?type=reportid=2266flag=C
Competitive Landscape Key Player:
- Amneal Pharmaceuticals Inc.
- Cardinal Health Inc.
- Cipla Ltd.
- Ipca Laboratories Ltd.
- Laurus Labs
- Lupin Limited
- Mylan N.V.
- Novartis AG
- Prasco Laboratories
- Reddy’s Laboratories Ltd.
- Sanofi S.A.
- Teva Pharmaceutical Industries Ltd.
- Torrent Pharma
- Zydus Cadila
Note: We are in the process of updating our reports. If you want to receive the latest research data covering the time period from 2023 to 2028, along with industry trends, market size, and competitive analysis, click on the request sample report. The team would be able to deliver the latest version of the report in a quick turnaround time.
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high-technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
Contact Us:
IMARC Group
Email: sales@imarcgroup.com
USA: +1-631-791-1145 | Asia: +91-120-433-0800
Address: 134 N 4th St. Brooklyn, NY 11249, USA
Follow us on Twitter: @imarcglobal
